병원 감염 치료제 시장 : 약제 클래스별, 투여 경로별, 원인 병원체군별, 용도별, 최종 사용자별, 주요 치료 대상 감염증별, 유통 채널별 시장 예측(2026-2032년)

The Hospital Infection Therapeutics Market is projected to grow by USD 15.85 billion at a CAGR of 5.43% by 2032.

Hospital infection therapeutics are shifting from reactive treatment toward evidence-led infection prevention, rapid diagnosis, antimicrobial stewardship, and targeted therapy. The clinical need remains substantial: the CDC reports that on any given day about 1 in 31 U.S. hospital patients has at least one healthcare-associated infection, while the WHO identifies antimicrobial resistance as one of the top global public health and development threats.

For care providers, the opportunity is tied to reducing bloodstream infections, surgical site infections, ventilator-associated pneumonia, catheter-associated urinary tract infections, and Clostridioides difficile infection. Hospitals increasingly need therapeutics and protocols that improve patient outcomes, limit avoidable complications, and protect antibiotic effectiveness through responsible use.

Transformative Shifts in the Hospital Infection Landscape

The hospital infection therapeutics landscape is being reshaped by antimicrobial resistance, aging inpatient populations, higher acuity care, invasive procedures, and stricter infection-control standards. The 2019 Global Burden of Disease analysis estimated 1.27 million deaths directly attributable to bacterial antimicrobial resistance and 4.95 million deaths associated with bacterial antimicrobial resistance, reinforcing the clinical urgency behind improved hospital infection management.

Providers are prioritizing pathogen-specific therapy, shorter treatment courses when clinically appropriate, combination regimens for resistant pathogens, and antimicrobial stewardship programs aligned with CDC, WHO, ECDC, and national guidelines. Purchasing decisions increasingly weigh real-world effectiveness, resistance impact, formulary value, diagnostic compatibility, safety profile, and infection-control performance.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is accelerating hospital infection therapeutics by improving early risk detection, diagnostic triage, antimicrobial selection, and surveillance of resistant organisms. AI-enabled models can analyze microbiology, pharmacy, electronic health record, imaging, and vital-sign data to support earlier intervention in sepsis, bacteremia, pneumonia, and multidrug-resistant infections.

The cumulative impact is operational as well as clinical. When governed carefully, AI can reduce diagnostic delays, flag inappropriate antibiotic use, support stewardship teams, identify infection clusters sooner, and strengthen antimicrobial resistance surveillance. Human clinical oversight remains essential because model bias, data quality, interoperability, and explainability directly affect patient safety and prescribing confidence.

Key Regional Insights

Asia-Pacific is experiencing rising demand for hospital infection therapeutics as large patient volumes, expanding tertiary care, medical technology adoption, and antimicrobial resistance increase treatment complexity. China and India are central to regional demand because of high inpatient volumes and national action plans on antimicrobial resistance, while Japan, South Korea, and Australia are advancing stewardship, hospital quality programs, and infection surveillance. ASEAN hospitals face uneven access to advanced diagnostics and newer antibiotics, making scalable stewardship and affordable therapeutics important regional priorities.

North America remains a strategically important region because of mature antimicrobial stewardship infrastructure, CDC and national surveillance systems, reimbursement scrutiny, and regulatory pathways supporting anti-infective development. Europe emphasizes coordinated resistance monitoring through ECDC-linked systems, strict antimicrobial governance, and health technology assessment discipline. Latin America shows growing need as Mexico and Brazil modernize hospital care while managing healthcare-associated infection risks and antimicrobial access challenges. The Middle East is supported by hospital infrastructure investment, medical tourism, and infection prevention initiatives, particularly in GCC countries. Africa faces a high burden of infectious disease and antimicrobial resistance, with demand shaped by diagnostic access, infection-control capacity, hospital infrastructure gaps, and the need for affordable, effective therapies.

Key Group Insights

ASEAN demand is shaped by dense urban hospitals, variable antimicrobial access, rising healthcare utilization, and the need for scalable stewardship across public and private systems. GCC countries are investing in advanced hospital infrastructure, accreditation, medical tourism, and infection prevention programs, supporting uptake of premium therapeutics, rapid diagnostics, and hospital-based antimicrobial stewardship.

The European Union drives policy-aligned prescribing, cross-border resistance monitoring, procurement discipline, and stewardship standards through coordinated health security and antimicrobial resistance initiatives. BRICS countries represent large-volume clinical need, but successful adoption depends on affordability, local evidence, manufacturing resilience, and alignment with national essential medicine and AMR strategies. G7 markets lead in innovation adoption, reimbursement evidence expectations, surveillance capability, and quality-based hospital procurement, while NATO members increasingly view antimicrobial resilience, supply continuity, and infection preparedness as part of broader health security planning.

Key Country Insights

The United States leads in antimicrobial stewardship implementation, CDC surveillance, hospital quality reporting, and adoption of advanced hospital infection therapeutics, while Canada emphasizes national antimicrobial resistance action, infection prevention, and hospital quality metrics. Mexico and Brazil face high demand for improved infection management as hospital modernization expands across public and private care, with stewardship and diagnostic access remaining key priorities.

The United Kingdom, Germany, France, Italy, and Spain prioritize stewardship, surveillance, antimicrobial prescribing standards, and health technology assessment, supporting evidence-based adoption of hospital infection therapeutics. Russia shows demand linked to hospital capacity, resistant pathogens, and modernization of infectious disease management. China and India are central volume markets due to large inpatient populations and national AMR priorities, Japan and South Korea lead in quality-focused adoption and advanced hospital practice, and Australia combines strict stewardship, infection-control standards, and surveillance-led decision-making to guide therapeutic use.

Actionable Recommendations for Industry Leaders

Hospital leaders should integrate therapeutics, diagnostics, infection prevention, and stewardship rather than treating them as separate purchasing categories. Priority actions include strengthening antibiogram use, aligning empiric therapy with local resistance patterns, deploying rapid diagnostics for high-risk infections, improving source control pathways, and reviewing antibiotic selection and duration through multidisciplinary stewardship teams.

Industry leaders should support hospitals with outcome-based evidence, pharmacoeconomic models, implementation resources, and education aligned with antimicrobial stewardship goals. Products that demonstrate reduced complications, optimized length of stay, fewer readmissions, improved safety, and resistance-conscious use will be better positioned in formularies, clinical pathways, and value-based procurement discussions.

Research Methodology

This executive summary is grounded in secondary research from globally recognized public health and regulatory sources, including WHO, CDC, ECDC, national antimicrobial resistance strategies, peer-reviewed burden-of-disease studies, and hospital infection-control guidance. Insights were assessed for relevance to therapeutics, stewardship, diagnostics, surveillance, procurement, and regional adoption dynamics.

The analysis emphasizes verified epidemiological signals, policy trends, clinical practice shifts, health system behavior, and market-access factors. No unverified market-size, market-share, or forecast claims are used; instead, the summary focuses on evidence-backed demand drivers and strategic implications for stakeholders in hospital infection therapeutics.

Conclusion

Hospital infection therapeutics are becoming a core pillar of patient safety, antimicrobial resilience, and hospital performance. Rising antimicrobial resistance, persistent healthcare-associated infections, and pressure to improve clinical outcomes are driving demand for targeted therapies, rapid diagnostics, surveillance-enabled stewardship, and infection-control aligned care models.

The strongest opportunities will emerge where clinical efficacy, responsible antibiotic use, diagnostic speed, and operational value intersect. Organizations that combine evidence generation, regional understanding, resilient access strategies, and digital decision support will be well positioned to address the next era of hospital infection management.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Hospital Infection Therapeutics Market, by Drug Class

• 7.1. Antibiotics
  • 7.1.1. Carbapenems
  • 7.1.2. Cephalosporins
  • 7.1.3. Fluoroquinolones
  • 7.1.4. Macrolides
  • 7.1.5. Penicillins
• 7.2. Antifungals
  • 7.2.1. Azoles
  • 7.2.2. Echinocandins
  • 7.2.3. Polyenes
• 7.3. Antiseptics
  • 7.3.1. Alcohol Based
  • 7.3.2. Chlorhexidine
  • 7.3.3. Iodophors
• 7.4. Antivirals
  • 7.4.1. Anti-HBV
  • 7.4.2. Anti-HCV
  • 7.4.3. Anti-HIV
  • 7.4.4. Anti-Influenza

8. Hospital Infection Therapeutics Market, by Route Of Administration

• 8.1. Inhalation
  • 8.1.1. Nebulized
  • 8.1.2. Dry-Powder
• 8.2. Oral
  • 8.2.1. Immediate-Release Oral
  • 8.2.2. Modified-Release Oral
• 8.3. Parenteral
  • 8.3.1. Intramuscular
  • 8.3.2. Intravenous
  • 8.3.3. Subcutaneous
• 8.4. Topical

9. Hospital Infection Therapeutics Market, by Causative Pathogen Group

• 9.1. Gram-Positive Bacterial Infection
  • 9.1.1. Staphylococcal Infection
  • 9.1.2. Enterococcal Infection
  • 9.1.3. Streptococcal Infection
• 9.2. Gram-Negative Bacterial Infection
  • 9.2.1. Enterobacterales Infection
  • 9.2.2. Pseudomonal Infection
  • 9.2.3. Acinetobacter
• 9.3. Anaerobic Bacterial Infection
• 9.4. Clostridioides Difficile Infection
• 9.5. Fungal Infection
  • 9.5.1. Candida Infection
  • 9.5.2. Aspergillus Infection
• 9.6. Polymicrobial Infection

10. Hospital Infection Therapeutics Market, by Application

• 10.1. Palliative
• 10.2. Prophylaxis
  • 10.2.1. Post-Operative
  • 10.2.2. Pre-Operative
• 10.3. Treatment
  • 10.3.1. Empirical
  • 10.3.2. Targeted Therapy

11. Hospital Infection Therapeutics Market, by End User

• 11.1. Ambulatory Surgery Centers
• 11.2. Clinics
• 11.3. Home Healthcare
• 11.4. Hospitals

12. Hospital Infection Therapeutics Market, by Primary Treated Infection

• 12.1. Lower Respiratory Tract Infection
• 12.2. Bloodstream And Intravascular Infection
• 12.3. Urinary Tract Infection
• 12.4. Intra-Abdominal Infection
• 12.5. Skin, Soft Tissue, And Surgical Wound Infection
• 12.6. Gastrointestinal Infection
• 12.7. Bone, Joint, And Device-Associated Infection
• 12.8. Central Nervous System Infection
• 12.9. Invasive Fungal Infection

13. Hospital Infection Therapeutics Market, by Distribution Channel

• 13.1. Hospital Pharmacy
• 13.2. Online Pharmacy
• 13.3. Retail Pharmacy
• 13.4. Wholesalers

14. Hospital Infection Therapeutics Market, by Region

• 14.1. Asia-Pacific
• 14.2. North America
• 14.3. Latin America
• 14.4. Europe
• 14.5. Middle East
• 14.6. Africa

15. Hospital Infection Therapeutics Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Hospital Infection Therapeutics Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025

18. Company Profiles

• 18.1. Alkem Laboratories Limited
• 18.2. Allecra Therapeutics GmbH
• 18.3. Amneal Pharmaceuticals, Inc.
• 18.4. Antibiotice S.A.
• 18.5. Astellas Pharma Inc.
• 18.6. Aurobindo Pharma Limited
• 18.7. Avenacy Inc.
• 18.8. Basilea Pharmaceutica Ltd.
• 18.9. Bayer AG
• 18.10. Centrient Pharmaceuticals Netherlands B.V.
• 18.11. Cidara Therapeutics, Inc.
• 18.12. Cipla Limited
• 18.13. CSPC Pharmaceutical Group Limited
• 18.14. Cumberland Pharmaceuticals Inc.
• 18.15. Dr. Reddy's Laboratories Limited
• 18.16. Fresenius SE & Co. KGaA
• 18.17. FUJIFILM Toyama Chemical Co., Ltd.
• 18.18. Gilead Sciences, Inc.
• 18.19. GSK plc
• 18.20. Harbin Pharmaceutical Group Co., Ltd.
• 18.21. Hikma Pharmaceuticals PLC
• 18.22. Iterum Therapeutics plc
• 18.23. JW Pharmaceutical Corporation
• 18.24. Lupin Limited
• 18.25. Lyfius Pharma Private Limited
• 18.26. Melinta Therapeutics, LLC
• 18.27. Merck & Co., Inc.
• 18.28. NextPharma Technologies
• 18.29. North China Pharmaceutical Co., Ltd.
• 18.30. Orchid Pharma Limited
• 18.31. Paratek Pharmaceuticals, Inc.
• 18.32. Pfizer Inc.
• 18.33. Sandoz Group AG
• 18.34. SCYNEXIS, Inc.
• 18.35. Shionogi & Co., Ltd.
• 18.36. SiNi Pharma Pvt Ltd
• 18.37. Spero Therapeutics, Inc.
• 18.38. Sun Pharmaceutical Industries Limited
• 18.39. Teva Pharmaceutical Industries Ltd.
• 18.40. USAntibiotics, LLC
• 18.41. Venatorx Pharmaceuticals, Inc.
• 18.42. Venus Remedies Limited
• 18.43. Viatris Inc.
• 18.44. WG Critical Care, LLC
• 18.45. Wockhardt Limited
• 18.46. Xellia Pharmaceuticals ApS
• 18.47. Zydus Lifesciences Limited